Please use this identifier to cite or link to this item: https://hdl.handle.net/10137/7766
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMeder KNen
dc.contributor.authorJayasinghe Sen
dc.contributor.authorBeard Fen
dc.contributor.authorDey Aen
dc.contributor.authorKirk Men
dc.contributor.authorCook Hen
dc.contributor.authorStrachan Jen
dc.contributor.authorSintchenko Ven
dc.contributor.authorSmith Hen
dc.contributor.authorGiele Cen
dc.contributor.authorHowden Ben
dc.contributor.authorKrause VLen
dc.contributor.authorMcIntyre Pen
dc.date2019en
dc.date.accessioned2019-09-02T23:25:34Zen
dc.date.available2019-09-02T23:25:34Zen
dc.date.issued2019-08-07en
dc.identifier.citationClinical infectious diseases : an official publication of the Infectious Diseases Society of America 2019-08-07en
dc.identifier.urihttps://hdl.handle.net/10137/7766en
dc.description.abstractUniversal pneumococcal conjugate vaccine (PCV) programs began in Indigenous Australian children in 2001 and all children in 2005, changing to PCV13 in 2011. We used laboratory data for invasive pneumococcal disease (IPD) and coded hospitalisations for non-invasive pneumococcal community acquired pneumonia (PnCAP) to evaluate long-term impact. Annual incidence (per 100,000 population) was calculated for age-specific total IPD, PCV13-non7v serotypes and PnCAP by Indigenous status. Incidence in the pre-universal PCV7 (2002-2004), early-PCV7 (2005-2007), pre-PCV13 (2008-mid 2011) and post-PCV13 (mid 2011-2016) periods was used to calculate incidence rate ratios (IRRs). In the total population, all-age incidence of IPD declined from 11.8 pre-PCV7 to 7.1 post-PCV13 (IRR 0.61, 95% CI 0.59-0.63) but for PnCAP declined <1 year (IRR 0.34, 95% CI 0.25-0.45) and 1-4 years (IRR 0.50, 95% CI 0.43-0.57) but increased significantly ≥5 years (IRRs 1.08 to 1.14). In Indigenous people, baseline PCV13-non7v IPD incidence was 3-fold higher, amplified by a serotype 1 epidemic in 2011. By 2015-6, although incidence of IPD and PnCAP in children <5 years decreased by 38%, neither decreased in people ≥5 years. 15 years post PCV and 5 years post PCV13, direct and indirect impact on IPD and PnCAP differed by age and between Indigenous and non-Indigenous people, with potential implications for long-term PCV impact in comparable settings.en
dc.language.isoengen
dc.subjectAustraliaen
dc.subjectimpacten
dc.subjectinvasive pneumococcal diseaseen
dc.subjectpneumococcal conjugate vaccinesen
dc.subjectpneumococcal pneumoniaen
dc.titleLong-term impact of pneumococcal conjugate vaccines on invasive disease and pneumonia hospitalisations in Indigenous and non-Indigenous Australians.en
dc.typeJournal Articleen
dc.identifier.journaltitleClinical infectious diseases : an official publication of the Infectious Diseases Society of Americaen
dc.identifier.doi10.1093/cid/ciz731en
dc.identifier.pubmedidhttps://www.ezpdhcs.nt.gov.au/login?url=https://www.ncbi.nlm.nih.gov/pubmed//31388670en
dc.identifier.affiliationNational Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children's Hospital at Westmead, Sydney, Australia.. National Centre for Epidemiology and Population Health, Australian National University, Canberra, Australia..en
dc.identifier.affiliationNational Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children's Hospital at Westmead, Sydney, Australia.. The University of Sydney, Sydney, Australia..en
dc.identifier.affiliationNational Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children's Hospital at Westmead, Sydney, Australia.. The University of Sydney, Sydney, Australia..en
dc.identifier.affiliationNational Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children's Hospital at Westmead, Sydney, Australia.. The University of Sydney, Sydney, Australia..en
dc.identifier.affiliationNational Centre for Epidemiology and Population Health, Australian National University, Canberra, Australia..en
dc.identifier.affiliationCentre for Disease Control, Northern Territory Department of Health, Darwin, Australia..en
dc.identifier.affiliationCommunicable Disease Epidemiology and Surveillance, Department of Health and Human Services, Melbourne, Australia..en
dc.identifier.affiliationThe University of Sydney, Sydney, Australia.. Centre for Infectious Diseases and Microbiology - Public Health, ICPMR, Westmead Hospital, Sydney, Australia..en
dc.identifier.affiliationPublic Health Microbiology, Forensic and Scientific Services, Queensland Department of Health, Coopers Plains, Australia..en
dc.identifier.affiliationPublic Health Division, Department of Health Western Australia, Perth, Australia..en
dc.identifier.affiliationMicrobiological Diagnostic Unit. Public Health Laboratory, Department of Microbiology & Immunology, University of Melbourne, Melbourne, Australia..en
dc.identifier.affiliationCentre for Disease Control, Northern Territory Department of Health, Darwin, Australia..en
dc.identifier.affiliationNational Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children's Hospital at Westmead, Sydney, Australia..en
Appears in Collections:(a) NT Health Research Collection

Files in This Item:
There are no files associated with this item.


Items in ePublications are protected by copyright, with all rights reserved, unless otherwise indicated.

Google Media

Google ScholarTM

Who's citing